About Motivation Assistance
Motivation Assistance provides assistance to HCPs to motivate for reimbursement of a medicine.
Motivation Assistance provides assistance to healthcare professionals to motivate for reimbursement of a medicine which requires a set of clinical criteria to be met prior to funding consideration. The goal of the motivation assistance tool is to decrease the barrier to funding and help healthcare professionals submit the correct information to medical schemes. The motivation tool is product specific and is sponsored by pharmaceutical companies. You will find the motivation assistance tool in certain sponsored product listings.
How to use the Motivation Assistance form:
Step 1: Click on the medicine tile you would like to access.
Step 2: Select the motivation assistance option
Step 3: Complete the form and submit to the medical scheme.
Medicines Motivation Assistance list:
Copellor
Click here to access the Copellor Motivation Assistance.
Copellor Active ingredient: Ixekizumab | Originator S4 | PFS | Aspen | Immunosuppressant
Copellor is indicated for:
- Plaque psoriasis
COPELLOR is indicated for the treatment of adult patients with moderate to severe plaque psoriasis who are candidates for systemic therapy. - Paediatric plaque psoriasis
COPELLOR is indicated for the treatment of moderate to severe plaque psoriasis in children from the age of 6 years and above with a body weight > 50 kg who are candidates for systemic therapy. - Psoriatic arthritis
COPELLOR, alone or in combination with methotrexate, is indicated for the treatment of active psoriatic arthritis in adult patients who have responded inadequately to, or who are intolerant to one or more disease-modifying anti-rheumatic drug (DMARD) therapies. - Axial spondyloarthritis
Ankylosing spondylitis (radiographic axial spondyloarthritis)
COPELLOR is indicated for the treatment of adult patients with active ankylosing spondylitis who have responded inadequately to conventional therapy. - Non-radiographic axial spondyloarthritis
COPELLOR is indicated for the treatment of adult patients with active non-radiographic axial spondyloarthritis with objective signs of inflammation as indicated by elevated C-reactive protein (CRP) and/or magnetic resonance imaging (MRI) who have responded inadequately to nonsteroidal anti-inflammatory drugs (NSAIDs).
Liptruzet®
Click here to access the Liptruzet® Motivation Assistance.
Liptruzet® Active ingredient: Ezetimibe/ Atorvastatin | Originator S4 | FCT | Organon| Lipid-modifying agent
Liptruzet® is indicated for the following:
- To reduce the risk of cardiovascular events in patients with coronary heart disease (CHD) and a history of acute coronary syndrome (ACS), either previously treated with a statin or not.
- Indicated as adjunctive therapy to diet for use in adults with primary (heterozygous familial and non-familial) hypercholesterolaemia or mixed hyperlipidaemia where use of a combination product is appropriate.
- Patients not appropriately controlled with a statin alone.
- Patients already treated with a statin and ezetimibe.
- Indicated as adjunctive therapy to diet for use in adults with HoFH. Patients may also receive adjunctive treatments (e.g. low-density lipoprotein [LDL] apheresis).
Ocrevus
Click here to access the Ocrevus® Motivation Assistance.
Ocrevus Active ingredient: Ocrelizumab | Originator| S4 | INF | Roche| Multiple Sclerosis | Anti-CD20 B-cell Therapy
Ocrevus® is the only therapy approved for both primary progressive multiple sclerosis (PPMS) and relapsing forms of multiple sclerosis (RMS).
Ocrevus® is indicated for:
- Patients with relapsing forms of multiple sclerosis (RMS) to suppress relapses and disease progression (clinical and subclinical disease activity).
- The first-line treatment of patients with primary progressive multiple sclerosis (PPMS) to delay disease progression and reduce deterioration in walking speed.
The medicine you want to motivate for is not listed here?
If you would like to get new medicines listed on the Motivation Assistance tool: Click here